Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088645900> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W3088645900 endingPage "S955" @default.
- W3088645900 startingPage "S955" @default.
- W3088645900 abstract "Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality, which has been approved for the treatment of glioblastoma. TTFields at specific frequency (150-200 kHz) are delivered via transducer arrays placed on the skin in proximity to the tumor site. TTFields predominantly act by disrupting the formation of the mitotic spindle during metaphase. TTFields were effective in multiple preclinical models of pancreatic cancer. The phase II PANOVA study, the first trial testing TTFields in pancreatic cancer patients, demonstrated the safety and preliminary efficacy of TTFields when combined with nab-paclitaxel and gemcitabine in both metastatic and LAPC. The phase III PANOVA-3 trial (NCT03377491) is designed to test the efficacy and safety of adding TTFields to nab-paclitaxel and gemcitabine combination in LAPC. Patients (N = 556) with unresectable, LAPC (per NCCN guidelines) will be enrolled in this prospective, randomized trial. Patients should have an ECOG score of 0-2 and no prior progression or treatment. Patients will be stratified based on their performance status and geographical region, and will be randomized 1:1 to TTFields plus nab-paclitaxel and gemcitabine or to nab-paclitaxel and gemcitabine alone. Chemotherapy will be administered at standard dose of nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2 once weekly). TTFields (150 kHz) will be delivered at least 18 hours/day until local disease progression per RECIST Criteria V1.1. Follow up will be performed q8w, including a CT scan of the chest and abdomen. Following local disease progression, patients will be followed monthly for survival. Overall survival will be the primary endpoint and progression-free survival, objective response rate, rate of resectability, quality of life and toxicity will all be secondary endpoints. Sample size was calculated using a log-rank test comparing time to event in patients treated with TTFields plus chemotherapy with control patients on chemotherapy alone. PANOVA-3 is designed to detect a hazard ratio 0.75 in overall survival. Type I error is set to 0.05 (two-sided) and power to 80%. NCT03377491. Novocure." @default.
- W3088645900 created "2020-10-01" @default.
- W3088645900 creator A5015800200 @default.
- W3088645900 creator A5039034056 @default.
- W3088645900 creator A5063282115 @default.
- W3088645900 creator A5065671989 @default.
- W3088645900 creator A5080481243 @default.
- W3088645900 date "2020-09-01" @default.
- W3088645900 modified "2023-09-30" @default.
- W3088645900 title "1567TiP A phase III trial of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3" @default.
- W3088645900 doi "https://doi.org/10.1016/j.annonc.2020.08.2050" @default.
- W3088645900 hasPublicationYear "2020" @default.
- W3088645900 type Work @default.
- W3088645900 sameAs 3088645900 @default.
- W3088645900 citedByCount "0" @default.
- W3088645900 crossrefType "journal-article" @default.
- W3088645900 hasAuthorship W3088645900A5015800200 @default.
- W3088645900 hasAuthorship W3088645900A5039034056 @default.
- W3088645900 hasAuthorship W3088645900A5063282115 @default.
- W3088645900 hasAuthorship W3088645900A5065671989 @default.
- W3088645900 hasAuthorship W3088645900A5080481243 @default.
- W3088645900 hasBestOaLocation W30886459001 @default.
- W3088645900 hasConcept C121608353 @default.
- W3088645900 hasConcept C126322002 @default.
- W3088645900 hasConcept C143998085 @default.
- W3088645900 hasConcept C2777292972 @default.
- W3088645900 hasConcept C2777844706 @default.
- W3088645900 hasConcept C2780210213 @default.
- W3088645900 hasConcept C2780258809 @default.
- W3088645900 hasConcept C71924100 @default.
- W3088645900 hasConceptScore W3088645900C121608353 @default.
- W3088645900 hasConceptScore W3088645900C126322002 @default.
- W3088645900 hasConceptScore W3088645900C143998085 @default.
- W3088645900 hasConceptScore W3088645900C2777292972 @default.
- W3088645900 hasConceptScore W3088645900C2777844706 @default.
- W3088645900 hasConceptScore W3088645900C2780210213 @default.
- W3088645900 hasConceptScore W3088645900C2780258809 @default.
- W3088645900 hasConceptScore W3088645900C71924100 @default.
- W3088645900 hasLocation W30886459001 @default.
- W3088645900 hasOpenAccess W3088645900 @default.
- W3088645900 hasPrimaryLocation W30886459001 @default.
- W3088645900 hasRelatedWork W1504271024 @default.
- W3088645900 hasRelatedWork W1975153720 @default.
- W3088645900 hasRelatedWork W2001578098 @default.
- W3088645900 hasRelatedWork W2024463098 @default.
- W3088645900 hasRelatedWork W2037231105 @default.
- W3088645900 hasRelatedWork W2091019843 @default.
- W3088645900 hasRelatedWork W2111373770 @default.
- W3088645900 hasRelatedWork W2165480504 @default.
- W3088645900 hasRelatedWork W2898524537 @default.
- W3088645900 hasRelatedWork W4238295572 @default.
- W3088645900 hasVolume "31" @default.
- W3088645900 isParatext "false" @default.
- W3088645900 isRetracted "false" @default.
- W3088645900 magId "3088645900" @default.
- W3088645900 workType "article" @default.